The current price of STOK is $26.07 — it has decreased by 5.03% since the previous close. Data as of Nov 5, 2026.
STOK is up 0.12% over the past week, up 2.96% over the past month and up 14.24% over the past year. The price is below its 200-day moving average of $30.89.
Analysts' average 12-month price target for STOK is $50.50, which implies 93.71% upside from the current price. Individual estimates range from $43.00 to $58.00.
Of the 14 analysts covering Stoke Therapeutics, Inc., 2 rate it a strong buy and 12 rate it a buy. The overall consensus is bullish. Analyst ratings are opinions and do not guarantee future performance.
Stoke Therapeutics, Inc. has a market capitalization of $1.69B. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.
In its most recent quarterly report, Stoke Therapeutics, Inc. posted a loss of $1.08 per share against an estimate of -$0.9291, missing expectations by 16.24%. Upcoming reports are listed in the earnings calendar.
Stoke Therapeutics, Inc. reported revenue of $11.26M in its most recent quarter, which has increased by 5.86% compared with the same quarter a year earlier. Analysts had expected $8.21M.
Stoke Therapeutics, Inc. has not paid any dividends over the past year.
Companies most comparable to Stoke Therapeutics, Inc. include Ionis Pharmaceuticals, Inc., Beam Therapeutics Inc., Silence Therapeutics plc, Wave Life Sciences Ltd. and Design Therapeutics, Inc.
In the latest trading session STOK moved between $25.94 and $27.50, a range of 5.98% of its current price.
Over the past 52 weeks STOK has traded between $21.68 and $40.22. The current price is 35.18% below its 52-week high.
Figures as of Nov 5, 2026. This information is provided for general purposes only and is not investment advice.